

Università degli Studi di Padova

Padua Research Archive - Institutional Repository

No association between the degree of liver steatosis and early signs of vasculopathy in T2DM.

Original Citation:

Availability:

This version is available at: 11577/2521592 since: 2016-06-29T09:51:27Z

Publisher:

Elsevier Science Publishers B.V.

Published version:

DOI:

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)



LETTER TO THE EDITOR

No association between the degree of liver steatosis and early signs of vasculopathy in T2DM

Non alcoholic fatty liver disease (NAFLD) is both an independent and an associated risk factor for cardiovascular (CV) disease in the general population [1]. Whereas the association between NAFLD, and early signs of vasculopathy, such as an increased intima-media thickness (IMT) and a decreased flow-mediated vasodilation (FMD), has been reported in the general population, such an association in type 2 diabetes mellitus (T2DM) is controversial. In T2DM patients with NAFLD FMD was decreased [2], whereas IMT was not different, with respect to patients without liver steatosis [3]. Should a (causative) relationship between hepatic steatosis and early signs of vasculopathy exists, the degree of liver fat should be associated with a worse endothelial function and morphology. However, despite the bulk of data generated on this complex association, insufficient reports exist on T2DM.

To this aim, we measured the extent of liver fat, average IMT, the presence and type of carotid plaques, and FMD, in sixty consecutive T2DM patients largely affected by features of the MS. Liver steatosis, IMT, and presence and types of carotid plaques, were evaluated by ultrasonography (using an HDI 5000 Philips Medical Systems apparatus, Bothell, WA, USA), with a broad-band width phased array transducer (2–5 MHz). Steatosis was divided into four classes following the traditional US classification (class 0: absence; classes 1–3: increasing degrees, of steatosis) [4]. IMT was assessed using standard procedures [5]. FMD was evaluated in 45 patients using an internationally validated approach [6]. Only six patients were current smokers, and seven had a positive history for CV disease (five for ischemic heart disease, and two for cerebrovascular disease). No subject was positive for hepatitis C virus infection.

The overall prevalence of steatosis was 88% (34% mild, 34% moderate e 20% severe). Average IMT was 0.88 ± 0.03 mm (Mean \pm SE), significantly greater ($p < 0.0001$) than the mean value of a healthy, age- and sex matched population at our Institution (0.72 ± 0.03 mm). Fifty-eight percent of patients had carotid plaques. Average FMD in the patients ($5.02 \pm 0.81\%$) was lower ($p < 0.001$) than the normal values of healthy, age- and sex matched individuals from our Institution ($6.56 \pm 0.60\%$).

Nevertheless, there was no difference, among the four classes of steatosis, in either FMD (class 0: $5.10 \pm 0.89\%$; class 1: $4.97 \pm 0.46\%$; class 2: $4.73 \pm 0.40\%$; class 3: $5.25 \pm 0.17\%$) ($p = 0.543$ by ANOVA), average IMT (0.82 ± 0.08 ; 0.93 ± 0.05 ; 0.85 ± 0.05 ; and 0.85 ± 0.06 mm, respectively; $p = 0.760$ by ANOVA), or the prevalence of carotid plaques (43; 70; 60 and 69% respectively, $p = 0.644$).

In conclusion, in T2DM patients largely exhibiting features of the MS, the degree of liver steatosis is not associated with early signs of (sub)clinical atherosclerosis and altered vascular function. These data question the role of liver fat as a direct determinant of early signs of vasculopathy in T2DM. Alternatively, it is possible that the burden of cardiovascular risk factors already present in these T2DM patients, obscure the possible contribution given by the degree of steatosis, on early signs of arteriosclerosis.

References

- [1] Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. *J Hepatol* 2008;49(4):600–7.
- [2] Kawashima S, Suzuki M, Kaneto H, Imano E, Haruna Y, Nishimura Y, et al. Insulin resistance and endothelial dysfunction in type 2 diabetic patients with non-alcoholic steatohepatitis. *Diabet Med* 2009;26(6):661–3.
- [3] Petit JM, Guiu B, Terriat B, Loffroy R, Robin I, Petit V, et al. Nonalcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. *J Clin Endocrinol Metab* 2009;94(10):4103–6.
- [4] Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. *Br Med J* 1986; 292:13–5.
- [5] Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarencu P, Bornstein N, et al. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. *Cerebrovasc Dis* 2007;23:75–80.
- [6] Corretti MC, Anderson TJ, Benjamin E, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the Ultrasound Assessment of endothelial-Dependent flow-mediated vasodilation of the Brachial Artery. A report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;39:257–65.

A. Coracina
*Metabolism Division, Dept. of Clinical and
Experimental Medicine, Policlinico Universitario,
via Giustiniani 2,
35128 Padua, Italy*

S. Gaiani
*Internal Medicine V, Dept. of Clinical and
Experimental Medicine, Policlinico Universitario,
via Giustiniani 2,
35128 Padua, Italy*

A. Cosma
*Metabolism Division, Dept. of Clinical and
Experimental Medicine, Policlinico Universitario,
via Giustiniani 2,
35128 Padua, Italy*

P. Pellizzari
*Dept. of Economics, University Ca' Foscari Venice,
873 S. Giobbe - Cannaregio, 30123 Venice, Italy*

C. Pizzi
*Dept. of Economics, University Ca' Foscari Venice,
873 S. Giobbe - Cannaregio, 30123 Venice, Italy*

S. de Kreutzenberg
*Metabolism Division, Dept. of Clinical and Experimental
Medicine, Policlinico Universitario, via Giustiniani 2,
35128 Padua, Italy*

D. Cecchet
*Metabolism Division, Dept. of Clinical and Experimental
Medicine, Policlinico Universitario, via Giustiniani 2,
35128 Padua, Italy*

D. Sacerdoti
*Internal Medicine V, Dept. of Clinical and Experimental
Medicine, Policlinico Universitario, via Giustiniani 2,
35128 Padua, Italy*

P. Tessari*
*Metabolism Division, Dept. of Clinical and Experimental
Medicine, Policlinico Universitario, via Giustiniani 2,
35128 Padua, Italy*

*Corresponding author. Tel.: +39 049 8211748;
fax: +39 049 8754179.

E-mail address: paolo.tessari@unipd.it

11 November 2011